Currently, additional in vivo and in vitro studies regarding NLRP3 blockage using the MCC950 pharmaceutical treatment are needed to determine whether the suppression of NLRP3-mediated signaling might stop the progression of PBC. The gene discussed is NLRP3; the disease is primary biliary cholangitis.